WO2006007400A9 - Methods of diagnosing and treating obesity, diabetes and insulin resistance - Google Patents
Methods of diagnosing and treating obesity, diabetes and insulin resistance Download PDFInfo
- Publication number
- WO2006007400A9 WO2006007400A9 PCT/US2005/021297 US2005021297W WO2006007400A9 WO 2006007400 A9 WO2006007400 A9 WO 2006007400A9 US 2005021297 W US2005021297 W US 2005021297W WO 2006007400 A9 WO2006007400 A9 WO 2006007400A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diagnosing
- diabetes
- methods
- insulin resistance
- treating obesity
- Prior art date
Links
- 206010022489 Insulin Resistance Diseases 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007516737A JP2008503212A (en) | 2004-06-16 | 2005-06-15 | Methods for diagnosis and treatment of obesity, diabetes and insulin resistance |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58044804P | 2004-06-16 | 2004-06-16 | |
US60/580,448 | 2004-06-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006007400A2 WO2006007400A2 (en) | 2006-01-19 |
WO2006007400A9 true WO2006007400A9 (en) | 2009-04-09 |
Family
ID=35784320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/021297 WO2006007400A2 (en) | 2004-06-16 | 2005-06-15 | Methods of diagnosing and treating obesity, diabetes and insulin resistance |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2008503212A (en) |
WO (1) | WO2006007400A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8734795B2 (en) | 2008-10-31 | 2014-05-27 | Biogen Idec Ma Inc. | Light targeting molecules and uses thereof |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2533667A1 (en) * | 2003-07-29 | 2005-02-10 | Universite Laval | Obesity markers and uses thereof |
GB0520568D0 (en) * | 2005-10-10 | 2005-11-16 | Paradigm Therapeutics Ltd | Receptor |
US20100298217A1 (en) * | 2007-05-30 | 2010-11-25 | Evan Richard Stanley | Csf-1r mutants |
KR101572162B1 (en) * | 2013-04-10 | 2015-11-26 | 한국생명공학연구원 | Regulation of brown adipocyte differentiation using PTP-RE |
WO2015200901A1 (en) | 2014-06-26 | 2015-12-30 | The Trustees Of Columbia University In The City Of New York | Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells |
US11291706B2 (en) | 2015-07-16 | 2022-04-05 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using Slit2 |
WO2017049010A1 (en) * | 2015-09-15 | 2017-03-23 | The Trustees Of Columbia University In The City Of New York | Use of aldehyde dehydrogenase as biomarker for beta-cell dysfunction and loss |
CA3071611A1 (en) | 2017-07-31 | 2019-02-07 | The Trustees Of Indiana University | Modified ddah polypeptides comprising a pharmacokinetic enhancing moiety, improved pharmacology and their uses |
US20230287432A1 (en) * | 2020-02-27 | 2023-09-14 | Alnylam Pharmaceuticals, Inc. | G protein-coupled receptor 146 (gpr146) irna compositions and methods of use thereof |
CN112472790B (en) * | 2020-12-25 | 2022-12-20 | 同济大学 | Application of small albumin inhibitor in preparing products for preventing and treating obesity and diseases caused by obesity |
-
2005
- 2005-06-15 JP JP2007516737A patent/JP2008503212A/en active Pending
- 2005-06-15 WO PCT/US2005/021297 patent/WO2006007400A2/en active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8734795B2 (en) | 2008-10-31 | 2014-05-27 | Biogen Idec Ma Inc. | Light targeting molecules and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2006007400A2 (en) | 2006-01-19 |
JP2008503212A (en) | 2008-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL246402A (en) | Therapeutic agent for treating obesity, diabetes and diseases associated with impaired glucose tolerance | |
HK1098700A1 (en) | Use of drug combinations for treating insulin resistance | |
EP2120959A4 (en) | Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia | |
EG25277A (en) | Subterranean treatment fluids, friction reducing copolymers, and associated methods. | |
WO2007100535A3 (en) | Oxyntomodulin derivatives | |
IL187859A0 (en) | Diagnosis and prognosis of diabetes | |
IL176648A0 (en) | (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity | |
PL1841363T3 (en) | Catheter-free implantable needle biosensor | |
GB0619860D0 (en) | Treatment of insulin resistance and disorders associated therewith | |
IL174033A0 (en) | Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent | |
EP1890708A4 (en) | Glucose inducible insulin expression and methods of treating diabetes | |
IL198112A0 (en) | 3-aminoimidazo [1,2-a]pyridine derivatives having an sglt1-and sglt2-inhibiting action for the treatment of type 1 and type 2 diabetes | |
EP1799217A4 (en) | Compounds and methods of treating insulin resistance and cardiomyopathy | |
GB2439838B (en) | Inter-system binding method and application based on hardware security unit | |
EP1794235A4 (en) | Electroconductive resin composition, production method and use thereof | |
WO2006007400A9 (en) | Methods of diagnosing and treating obesity, diabetes and insulin resistance | |
EP1733749A4 (en) | Syringe with connector, connector for syringe, and syringe | |
EP1825002A4 (en) | Markers for metabolic syndrome obesity and insulin resistance | |
WO2003102163A8 (en) | Methods of diagnosing and treating diabetes and insulin resistance | |
EP1774029A4 (en) | Method for detecting the risk of and for treatment of type 2 diabetes | |
AU2003243427A1 (en) | Methods of diagnosing and treating diabetes and insulin resistance | |
AU2001292658A1 (en) | Method for treatment of insulin resistance in obesity and diabetes | |
ATE504595T1 (en) | IL-22 FOR THE TREATMENT OF OBESITY, DIABETES, HYPERLIPIDEMIA, HYPERGLYCEMIA AND INSULIN RESISTANCE | |
HK1076721A1 (en) | A chinese traditional medical composition for treating diabetes and method for preparing the same | |
EP1984734B8 (en) | Sigma-2 receptor, method of screening of specific ligands and use of the same in diagnostic or therapeutic methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007516737 Country of ref document: JP |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |